Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

The Effect of Sarcopenia on the Efficacy and Prognosis of HCC Treated With Lenvatinib and Anti-PD-1 Treatment

Authors not listed

First Affiliated Hospital of Wenzhou Medical University · 2022

Abstract

Sarcopenia is associated with the prognosis of HCC and cholangiocarcinoma. But there has been rare study focusing on the effect of sarcopenia on the prognosis of HCC treated with lenvatinib and anti-PD1.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-03 MST

Cite this

APA
Anonymous. (2022). The Effect of Sarcopenia on the Efficacy and Prognosis of HCC Treated With Lenvatinib and Anti-PD-1 Treatment. <em>First Affiliated Hospital of Wenzhou Medical University</em>. https://clinicaltrials.gov/study/NCT05443230
Vancouver
Anonymous. The Effect of Sarcopenia on the Efficacy and Prognosis of HCC Treated With Lenvatinib and Anti-PD-1 Treatment. First Affiliated Hospital of Wenzhou Medical University. 2022.
BibTeX
@misc{anon2022TheEff, title = {The Effect of Sarcopenia on the Efficacy and Prognosis of HCC Treated With Lenvatinib and Anti-PD-1 Treatment}, author = {Anonymous}, journal = {First Affiliated Hospital of Wenzhou Medical University}, year = {2022}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings

Wiener Medizinische Wochenschrift 2018
Citation only

Sarcopenia

▲ 102
Clinics in Geriatric Medicine 2010
Citation only

Sarcopenia

▲ 94
Clinics in Geriatric Medicine 2017
Citation only

Sarcopenia

▲ 125